Forte Biosciences, Inc. financial data

Symbol
FBRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
3060 Pegasus Park Drive, Building 6, Dallas, Texas
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Tocagen Inc (to 6/15/2020)
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 711 % -52.6%
Return On Equity -99.4 % -110%
Return On Assets -85.7 % -93.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.4 M shares +73.5%
Common Stock, Shares, Outstanding 36.4 M shares +73.3%
Entity Public Float 20.4 M USD +16.6%
Common Stock, Value, Issued 36 K USD +71.4%
Weighted Average Number of Shares Outstanding, Basic 21 M shares +42.6%
Weighted Average Number of Shares Outstanding, Diluted 21 M shares +42.6%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 12 M USD +40.4%
Operating Income (Loss) -33.4 M USD -83.3%
Net Income (Loss) Attributable to Parent -32.1 M USD -77.9%
Earnings Per Share, Basic -0.84 USD/shares +11.6%
Earnings Per Share, Diluted -0.84 USD/shares +11.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 30.4 M USD -15.2%
Assets, Current 31.5 M USD -13.1%
Property, Plant and Equipment, Net 106 K USD
Other Assets, Noncurrent 409 K USD -6.41%
Assets 32 M USD -12.8%
Accounts Payable, Current 1.69 M USD +25.6%
Accrued Liabilities, Current 1.65 M USD -31.9%
Liabilities, Current 3.33 M USD -11.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2 K USD
Retained Earnings (Accumulated Deficit) -126 M USD -34.3%
Stockholders' Equity Attributable to Parent 28.7 M USD -12.9%
Liabilities and Equity 32 M USD -12.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.67 M USD -28.1%
Net Cash Provided by (Used in) Financing Activities -8 K USD -233%
Net Cash Provided by (Used in) Investing Activities 47 K USD
Common Stock, Shares Authorized 200 M shares 0%
Common Stock, Shares, Issued 36.4 M shares +73.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.68 M USD -28.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 30.4 M USD -15.2%
Deferred Tax Assets, Valuation Allowance 18.6 M USD +52.3%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 18.6 M USD +52.3%
Depreciation 9 K USD
Payments to Acquire Property, Plant, and Equipment 6 K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -32.1 M USD -9.97%
Property, Plant and Equipment, Gross 124 K USD
Deferred Income Tax Expense (Benefit) 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 6.52 M USD +7.88%
Current Income Tax Expense (Benefit) 0 USD
Share-based Payment Arrangement, Expense 3.21 M USD -16.3%